← Back to headlines
AbbVie Q1 Preview: Skyrizi and Rinvoq Expected to Drive Growth
AbbVie's Q1 earnings preview indicates that its drugs Skyrizi and Rinvoq are anticipated to be key drivers for growth recovery in the upcoming financial report.
28 Apr, 14:15 — 28 Apr, 14:15
Sources
Showing 1 of 1 sources
